SCHEMBL28997883

SCHEMBL28997883

CN(CCCNCCCO)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.44
CA14 Q9ULX7 1/20 0.43
CTSK P43235 3/20 0.37
PAOX Q6QHF9 2/20 0.37
METAP2 P50579 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
FPR3 P25089 1/20 0.33
FPR2 P25090 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
KDM4E B2RXH2 2/20 0.33
PTGS1 P23219 1/20 0.33
KCNH2 Q12809 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30999444 0.95 TDP1 (0.42) TDP1CA14CTSKPAOXMETAP2
SCHEMBL25352467 0.92 CA14 (0.48) TDP1CA14CTSKPAOXMETAP2
SCHEMBL22771101 0.89 CA14 (0.42) TDP1CA14CTSKPAOXMETAP2
SCHEMBL1094425 0.88 TDP1 (0.42) TDP1CA14CTSKMETAP2HDAC1
SCHEMBL2478206 0.86 TDP1 (0.44) TDP1CA14CTSKMETAP2HDAC1
SCHEMBL15223854 0.85 PAOX (0.46) TDP1CA14CTSKPAOXMAOA
SCHEMBL20067555 0.85 CA14 (0.41) TDP1CA14CTSKPAOXMETAP2
SCHEMBL20763732 0.84 TDP1 (0.50) TDP1CA14CTSKMAOAMAOB
SCHEMBL20763276 0.84 TDP1 (0.54) TDP1CA14CTSKMAOAMAOB
SCHEMBL17267507 0.84 TDP1 (0.47) TDP1CA14CTSKMETAP2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 US disclosed
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-18 US disclosed
EP-4182308-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-05-24 EP disclosed
CN-116096719-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2023-05-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 TDP1 2987/4885CA14 4703/4885CTSK 4349/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 TDP1 2987/4885CA14 4703/4885CTSK 4349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.